Journalism of Courage
SMART STOCKS NEWS
Kissht’s rapid rise: Can its business justify the valuation?Subscriber Only
August 5, 2026 06:58 IST
Kissht is up 86% in three months since listing. A 61% growth rate, 5% RoAA and a 2.1% GNPA, but credit costs remain above 8%. At 2.4x book, what exactly are investors paying for?
Sona Comstar is betting on a 10x decade. Can execution match the ambition?Subscriber Only
July 30, 2026 06:30 IST
Sona Comstar has transformed itself from a precision auto-components maker into a diversified technology player spanning EVs, sensors, railways and robotics. As it targets another 10x growth over the next decade, can its acquisition-led strategy deliver?
Concord Biotech: A bad year or a bigger opportunity?Subscriber Only
July 22, 2026 07:30 IST
Concord Biotech had its toughest year as a listed company, with revenue and profit falling sharply. But a closer look reveals a business with strong positions in niche fermentation-based APIs, significant spare capacity and potential operating leverage. The question is whether FY26 was a temporary setback, or the start of a structural slowdown.
PCBL Chemicals: Can its diversification drive the next growth cycle?Subscriber Only
July 11, 2026 08:26 IST
India's largest carbon black producer is transforming into a specialty chemicals company through phosphonates, specialty black, and battery materials. But after a weak FY26, can these bets reignite earnings?
AAA rating, 0.55% ROA: What Emirates NBD really bought in RBL BankSubscriber Only
July 7, 2026 06:30 IST
RBL Bank has a new owner, an AAA credit rating and Rs 26,016 crore in fresh capital. Yet its return on assets remains just 0.55%. As Emirates NBD bets on the lender's future, the bigger question is whether a stronger balance sheet can translate into stronger earnings.
Aarti Pharmalabs: Can its CDMO bet revive growth after a weak year?Subscriber Only
July 2, 2026 06:43 IST
A caffeine giant, a growing CDMO business, and a recovering API segment. Can Aarti Pharmalabs convert a Rs 1,300+ crore capex cycle into a compounding pharma platform?
Centum Electronics: Why a Rs 52-crore loss hasn’t derailed the rallySubscriber Only
June 26, 2026 06:30 IST
Reported a Rs 52-crore FY26 loss and a negative P/E, yet Centum Electronics trades near record highs. A one-time cleanup has revealed a faster-growing India business. The question now: does 50x earnings still make sense?
Syngene International: Could India’s WuXi moment finally be here?Subscriber Only
June 23, 2026 06:30 IST
A difficult FY26, years of capability building, and the Pentagon's designation of WuXi AppTec may be converging to create the biggest opportunity in Syngene's history.
WPIL’s Rs 6,000-cr order book is growing. Why isn’t the market convinced?Subscriber Only
June 17, 2026 13:43 IST
WPIL's stock has halved as its domestic business stumbled, but strong international operations have cushioned the blow. With a record order book and a valuation of just 2.7 times book value, can fresh project wins and improved cash generation drive the next leg of growth?
Honasa Consumer is growing again, but can it keep margins intact?Subscriber Only
June 16, 2026 06:30 IST
EBITDA tripled, PAT jumped 2.7x, and Honasa declared its first dividend. But margins expanded because advertising costs fell, not because the business became structurally more profitable. At 66x earnings, is the turnaround real, or has the market already priced it in?
After a 38% rally, can VA Tech Wabag deliver more?Subscriber Only
June 16, 2026 11:06 IST
The business transformed first. The stock followed later. After years of being overlooked, VA Tech Wabag has been re-rated sharply. The question now is whether its growth, cash generation and order pipeline justify 27x earnings.
Can Supriya Life Sciences unlock its next leg of growth beyond APIs?Subscriber Only
June 6, 2026 06:30 IST
Over the last few years, Supriya Life Sciences has expanded beyond its traditional API business. By targeting markets dominated by Chinese suppliers and investing in formulations, contrast media APIs, peptides, and CDMO services, the company is increasing its presence across the pharmaceutical value chain. The key question is whether these initiatives can transform it into a diversified pharmaceutical player.
Gujarat Themis Biosyn’s Rs 3,000 crore bet: Can it build a global pharma platform?Subscriber Only
June 3, 2026 10:51 IST
A small-cap API intermediate manufacturer is attempting a transformation into a global pharmaceutical platform through Rs 3,000 crore of acquisitions, including Sanofi's anti-TB brands and Japan's MicroBiopharm. The opportunity is compelling, but can the balance sheet support the ambition?
From scooter frames to satellite parts: Belrise’s quiet push into the global aerospace supply chainSubscriber Only
May 30, 2026 06:30 IST
A 2W-metal company is quietly buying its way into aerospace and satellite supply chains. It saw its FY26 profit after tax jump 41%, reduced its net debt to near zero, and watched its stock double. At ~40x, is the aerospace bet already in the price?
Specialty chemicals, peptides, and pricing recovery: The Alkyl Amines opportunitySubscriber Only
May 27, 2026 11:45 IST
Alkyl Amines Chemicals manufactures critical reagents used in peptide synthesis and pharmaceutical chemistry. With global leadership in several amine molecules and exposure to the GLP-1 ecosystem, the company is emerging as a key beneficiary of India’s pharmaceutical manufacturing scale-up. The question now is whether execution can keep pace with the scale of the opportunity.
Manorama Industries: Can growth sustain the valuation?Subscriber Only
May 21, 2026 06:30 IST
Manorama Industries’ FY26 revenue grew 76%, ROE touched 40%, and EBITDA margin expanded to 27%. The stock now trades at 34x earnings. But after two years of negative operating cash flow before a sharp rebound in FY26, the key question is whether margins, capacity expansion, pricing power, and cash conversion can continue to hold together.
Acutaas Chemicals: The specialty chemicals story the market is re-rating fastSubscriber Only
May 18, 2026 06:30 IST
Acutaas Chemicals was once viewed primarily as a pharmaceutical intermediates manufacturer. Today, the company is building a broader specialty chemicals platform spanning CDMO, battery electrolyte additives, semiconductor chemicals, and fine chemistry. As multiple growth engines begin scaling simultaneously, the key question is whether execution can justify the sharp valuation re-rating already underway.
45% EPS CAGR, 29% ROE: What’s driving Solar Industries’ growth?Subscriber Only
May 16, 2026 10:03 IST
A Rs 21,200 crore order book, the commercial rollout of Pinaka rockets, and rapidly scaling international defence orders are transforming Solar Industries from an industrial explosives maker into one of India’s fastest-growing defence manufacturers. Investors are now watching whether this momentum can sustain the company’s next phase of compounding.
Rs 2,170 crore in gross bookings, Rs 24 crore EBITDA: So why is Yatra stock still down?Subscriber Only
May 7, 2026 06:30 IST
Yatra Online Ltd continues to grow bookings, revenue, and profitability, yet the stock has corrected sharply from its highs. With corporate travel, higher-margin segments, and platform expansion now driving strategy, the market is no longer asking whether Yatra can grow, but whether it can deliver consistent, predictable earnings over time.
After a 4x rally and 92.5% EBITDA surge, what lies ahead for MTAR Technologies?Subscriber Only
May 2, 2026 06:35 IST
For years, MTAR Technologies operated under the radar, building components across nuclear, clean energy, and defence. Now, as global demand converges across these sectors, its order book is surging and capacity is stretched. With deep technical moats and multiple growth engines firing at once, the question now is: are the valuations stretched?
CP PLUS hits 39% market share, but can it hold on?Subscriber Only
April 29, 2026 06:30 IST
In Q3 FY26, CP Plus's revenue grew 37% year-on-year, while adjusted PAT surged 139% and EBITDA margins expanded from 8.3% in FY25 to 12.7%. In a weak broader market, such momentum raises two questions: what is driving this transformation, and do current valuations still hold up?
ITC stock at 3-year low: 3 reasons the cigarette giant is under pressureSubscriber Only
April 28, 2026 06:30 IST
ITC Limited shares have underperformed both cigarette peers and the broader FMCG pack, as the excise duty hike intensifies concerns over a potential shift toward illicit trade. Long-term investors should closely monitor FY27 earnings, when the full impact of the tax changes is likely to become evident.
Campus Activewear: Rs 588 crore quarter, strong margins — Is the opportunity still open?Subscriber Only
April 23, 2026 06:30 IST
In the last quarter, Campus Activewear reported revenue of Rs 588 crore, EBITDA of Rs 115.8 crore, and PAT of Rs 63.7 crore. The bigger question, however, is whether this marks the beginning of a sustained shift toward a more premium, higher-margin business, or simply a strong phase in a cyclical consumer category.
Natco Pharma: A high-margin business or a volatility trap at 10x earnings?Subscriber Only
April 22, 2026 06:30 IST
Despite 30%+ margins and exposure to the GLP-1 opportunity, Natco Pharma continues to trade at a modest valuation. Is the 10x P/E a structural constraint or a mispriced opportunity?
53 million tonnes output, 33% margins, 10x earnings: NMDC’s volume-price paradoxSubscriber Only
April 15, 2026 06:30 IST
NMDC just delivered its best year ever, crossing 50 million tonnes of iron ore production. But falling prices, rising costs, and Rs 10,000+ crore stuck in receivables are keeping profits, and the stock, under pressure.
Advertisement
Hunter Biden reveals new details of Joe Biden’s ‘painful cancer’ battle
World4 hr ago
Former US President Joe Biden’s prostate cancer has spread to his bones and is causing him significant pain, his son Hunter Biden said. Hunter, who was speaking in a BBC interview broadcast, became emotional while discussing his father’s health and described the situation as difficult for the family.
BEST OF EXPRESS
Advertisement
Must Read
Advertisement
